Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on April 16, 2019. The filing discloses a strategic collaboration and license agreement entered into with BioSense Global LLC to advance the development and commercialization of the company's lead asset, RX-3117, for pancreatic and other cancers in specific Asian territories.
Key Financial Metrics
The filing details specific financial terms of the new agreement but does not provide consolidated revenue, profit, cash flow, or balance sheet data for the company.
- Upfront Payment: Aggregate of $3.0 million ($1.5 million paid immediately; $1.5 million due August 24, 2019).
- Milestone Payments: Potential aggregate of up to $226 million contingent on development, regulatory, and commercial achievements.
- Royalties: Tiered royalties in the low double digits to mid-teens on annual net sales within the territory.
Material Changes
The primary material change is the execution of the Collaboration and License Agreement with BioSense Global LLC. This agreement grants BioSense an exclusive license to develop and commercialize RX-3117 for metastatic pancreatic cancer in Singapore, China, Hong Kong, Macau, and Taiwan. Additionally, BioSense will conduct a Phase 2 clinical trial in China for up to three additional indications at its sole expense, while Rexahn will supply the drug for the trial at its own expense.
Outlook, Risks, and Contingencies
Outlook: The agreement positions Rexahn to receive significant potential future cash flows through milestones and royalties while offloading development costs for the Asian market to BioSense. Rexahn retains the right to include Chinese sites in global registration-enabling trials for the lead indication.
Risks and Contingencies:
- The remaining $1.5 million upfront payment is contingent on being paid by August 24, 2019; failure to pay allows Rexahn to terminate the agreement.
- BioSense may terminate the agreement regarding specific indications if clinical trials fail.
- The agreement is subject to termination for material breach, insolvency, or drug safety issues.
- The full text of the agreement is not included in this filing and will be filed in the subsequent Form 10-Q.
Investor Verification Checklist
- Verify the receipt of the initial $1.5 million upfront payment in the company's cash balance.
- Monitor the payment status of the remaining $1.5 million due on August 24, 2019.
- Review the full Collaboration and License Agreement when filed as an exhibit to the June 30, 2019 Form 10-Q for detailed termination clauses and milestone definitions.
- Confirm the timeline and scope of the Phase 2 clinical trial to be conducted by BioSense in China.